Botanical Dermatology Brand Kamedis Forms U.S. Medical Advisory Board

SAN FRANCISCO, March 19, 2018 /PRNewswire/ -- Kamedis™, a provider of advanced botanical solutions for chronic skin disorders, today announced the formation of a U.S. medical advisory board to support the Israeli-based company's launch in the U.S. The company's clinically proven OTC solutions for eczema, acne and dandruff combine patented botanical combinations derived from traditional Chinese medicine with active OTC ingredients used in Western pharmacology to provide safe, effective alternatives for consumers struggling with difficult skin conditions.

The Kamedis product lines currently being introduced in the U.S. have been clinically proven to reduce eczema flare-ups up to 50% in two weeks, acne lesions within 12 hours, and dandruff by 50% in two weeks without complications like drying, flaking and irritation or undesirable ingredients such as benzoyl peroxide, sodium lauryl sulfate, parabens, steroids, dyes and coal tar.

The new U.S. medical advisory board uniquely combines dermatologists and naturopaths, reflecting Kamedis' melding of different approaches to medical challenges. Board members will supply scientific and medical expertise as well as strategic advice to assist Kamedis in building its U.S. market presence. Members include:

• Zoe Draelos, MD, FAAD, a clinical and research dermatologist with a private solo practice in High Point, NC, who is also a Consulting Professor of Dermatology at Duke University. Dr. Draelos has authored 12 textbooks, served as the principal investigator on more than 400 studies, and heads a consulting firm that provides research, consulting, marketing, and communication services to the pharmaceutical and cosmetics industries.
• Lawrence Green, MD, FAAD, a Rockville, MD-based dermatologist and Assistant Clinical Professor of Dermatology at George Washington University School of Medicine. Dr. Green is frequently consulted on conditions like acne and psoriasis, author of The Dermatologist's Guide to Looking Younger, and frequent Capitol Hill visitor seeking research funding for skin disease and physician/patient advocacy issues.
• Leon Kircik, MD, FAAD, is the Medical Director of DermResearch, PLLC and Physicians Skin Care, PLLC in Louisville, Kentucky, as well as Associate Clinical Professor of Dermatology at Indiana University Medical Center and Icahn School of Medicine at Mount Sinai Medical Center. He has been the principal investigator of clinical trials for conditions including psoriasis, acne, rosacea and atopic dermatitis.
• Daniel Siegel, MD, FAAD, is a Clinical Professor of Dermatology at SUNY Downstate and a former President of the American Academy of Dermatology. He is also in private practice with Long Island Skin Cancer and Dermatologic Surgery in Smithtown, NY. Dr. Siegel is the recipient of multiple awards including the Academy of Dermatology Presidential Citation which he has received five times.
• Michael Traub, ND, former president of the American Association of Naturopathic Physicians, author of Essentials of Dermatological Diagnosis and Integrative Therapeutics, and recipient of the AANP Physician of the Year award in 2006. He has been medical director of Lokahi Health Center in Kailua Kona, Hawaii since 1986 and actively engaged in research and healthcare policy issues throughout his career.

"We introduced our first products in Israel in 2007 and since then have expanded to China, Taiwan, Hong Kong, Switzerland and the Philippines. The U.S. market presents a whole new set of challenges and opportunities," said Kamedis Inc. CEO Roni Kramer, a traditional Chinese medicine practitioner who founded the company after discovering that botanicals helped dermatologic patients who experienced side effects or no relief from conventional products. "Our medical advisory board will be instrumental in guiding our efforts to establish the brand here, support ongoing product development and clinical trial initiatives, and ensure that consumers have truly effective nonsteroidal alternatives to treat chronic skin disorders."

About Kamedis

Kamedis develops effective, dermatologist-tested, botanical skincare products for a variety of chronic skin conditions including eczema, acne, dandruff, psoriasis, dry skin and itchy/irritated skin. Launched in Israel in 2003 and now sold worldwide, the company's products are based on extensive scientific research and development that included testing hundreds of traditional Chinese medicine botanicals and their combinations. The botanicals are produced in an ISO 13485- and ISO 9001-certified manufacturing facility ensuring quality and production consistency of botanical extracts. The unique extraction technique is developed to maximize formulation potency. All final products have been validated by dermatologists, are backed by dozens of clinical trials, and have received strong endorsement from consumers. For more information, visit https://kamedis-usa.com or email [email protected]. 

SOURCE Kamedis

Related Links

http://kamedis-usa.com